"If Berkshire ever gets in trouble, it will be my fault."

Today I finally made my way through Berkshire Hathaway's 2009 annual report, which was released last week.

I'm kind of biased, because I weirdly enjoy reading SEC filings, but I really think anyone could have a good time leafing through Berkshire's annual earnings report. Warren Buffett writes it himself in a conversational tone, sprinkling in his investment philosophies and personal anecdotes with the required facts and figures. I wish more public companies would follow Buffett's lead in making shareholder updates as interesting as they are informative.

I particularly liked his assertion that a CEO should man up and accept full responsibility for the performance of his (or her) company.

"I believe that a CEO must not delegate risk control. It’s simply too important. ...If Berkshire ever gets in trouble, it will be my fault. It will not be because of misjudgments made by a Risk Committee or Chief Risk Officer.

In my view a board of directors of a huge financial institution is derelict if it does not insist that its CEO bear full responsibility for risk control. If he’s incapable of handling that job, he should look for other employment."
Comments
By rotbapy at 2:18 p.m. Nov. 18, 2022
Purpose To evaluate the efficacy and tolerability of fulvestrant Faslodex; AstraZeneca Pharmaceuticals LP, Wilmington, DE, a new estrogen receptor ER antagonist that downregulates ER and has no agonist effects, versus tamoxifen, an antiestrogen with agonist and antagonist effects, for the treatment of advanced breast cancer in postmenopausal women <a href=https://clomid.mom/>clomid generic</a> To assess synaptic coupling between IHCs and afferent SGNs in Nptn tm1b mice, we performed whole mount immunolabeling of cochleae, using an anti Ribeye antibody pre synaptic ribbon and an anti GluR2 antibody post synaptic density Fig 6A
By shufali at 4:01 a.m. Nov. 22, 2022
<a href=http://lasix.autos/>torsemide to lasix conversion calculator</a> You can manage constipation in a variety of ways
By nandoxfex at 11:25 a.m. Dec. 9, 2022
Criticisms of the use of surrogate endpoints for overall survival are that they may be prone to investigator bias and sensitive to the time of assessment, making them potentially unsuitable for cohort studies and non blinded randomized trials 34 and that they may not reflect clinically meaningful outcomes 14 <a href=https://sviagras.cyou>how many beers can you have with viagra</a>
New comment